Track market-moving stories before they get noisy

Vancouver, British Columbia--(Newsfile Corp. - May 19, 2026) - Starcore International Mines Ltd. (TSX: SAM) ("Starcore" or "the Company") announces production results for the fourth fiscal quarter ended April 2026 at its San Martin Mine ("San Martin") in Querétaro, Mexico.

In this quarter we encountered lower grades and tonnage processed. This was due mainly to the fact that the high-grade Manto reserves, which were detected using diamond drilling in the previous quarter, were found to be located between a fault at the top of the Manto and very soft material at the bottom. This makes mining very difficult and is subject to higher dilution. We quickly adjusted to prepare a new high-grade ore body in another area of ​​the mine to counteract this effect, and this new ore body was reached by the end of the quarter.

The geophysical survey announced in the previous quarter was carried out consisting of two surveys: a mobile MT (Magneto Telluric) geophysical survey conducted by Expert Geophysics, covering a total of 91.5 square kilometers, and an IP (Induced Polarization) geophysical survey by Geotem, covering a total of 5.2 square kilometers. The results of the surveys are expected to be known by the end of May. With this, we have practically covered 70% of the 13,000-hectare concession.

"At this time we are focused on increasing the production of ounces in both the oxide ore and the carbonaceous ore, which was producing results from the second half of April. The Carbonaceous ore being processed through the plant is averaging 3 g/t of gold and 25 g/t of silver at a recovery of approximately 80% with milling reaching 100 tons per day by quarter end," stated Salvador García, the Company's Chief Operating Officer.

     12 Month YTD   San Martin Production Q4 2026 Q3 2026 Q/Q Change 2026 2025 Y/Y Change Ore Milled (Tonnes) 45,550 52,609 -13% 204,366 197,880 3 % Gold Equivalent Ounces 1,722 2,162 -20% 7,874 8,916 -12% Gold Grade (Grams/Ton) 1.23 1.33 -8% 1.35 1.58 -15% Silver Grade (Grams/Ton) 17.33 18.29 -5% 15.67 14.27 10% Gold Recovery (%) 84.17 85.72 -2% 80.84 82.73 -2% Silver Recovery (%) 44.85 46.37 -3% 48.52 54.09 -10% Gold: Silver Ratio 61.71 60.42  72.15 85.57 Salvador Garcia, B. Eng., a director of the Company and Chief Operating Officer, is the Company's qualified person on the project as required under NI 43-101and has prepared the technical information contained in this press release.

About Starcore

Starcore International Mines is engaged in precious metals production with focus and experience in Mexico. The Company's base of producing assets includes its gold-producing San Martin Mine and the La Tortilla silver mine, both in the state of Querétaro, Mexico. The Company is a leader in Corporate Social Responsibility and advocates value driven decisions that will increase long term shareholder value. You can find more information on the investor friendly website here: www.starcore.com.

ON BEHALF OF STARCORE INTERNATIONAL

MINES LTD

Signed "Robert Eadie"
Robert Eadie, Chief Executive Officer

FOR FURTHER INFORMATION PLEASE CONTACT:

ROBERT EADIE
Telephone: (604) 602-4935

LinkedIn
Twitter
Facebook

The Toronto Stock Exchange has not reviewed nor does it accept responsibility
for the adequacy or accuracy of this press release.

This news release contains "forward-looking" statements and information ("forward-looking statements"). All statements, other than statements of historical facts, included herein, including, without limitation, management's expectations and the potential of the Company's projects, are forward-looking statements. Forward-looking statements are based on the beliefs of Company management, as well as assumptions made by and information currently available to Company's management and reflect the beliefs, opinions, and projections on the date the statements are made. Forward-looking statements involve various risks and uncertainties and accordingly, readers are advised not to place undue reliance on forward-looking statements. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. The Company assumes no obligation to update forward‐looking statements or beliefs, opinions, projections or other factors, except as required by law.

NOT FOR DISTRIBUTION IN THE UNITED STATES

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/297750

Source: Starcore International Mines Ltd.

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Vancouver, British Columbia--(Newsfile Corp. - May 27, 2026) - Starcore International Mines Ltd. (TSX: SAM) ("Starcore" or "the Company") announces that its wholly-owned Mexican subsidiary, Compañía Minera Peña de Bernal S.A. de C.V. ("CMPB"), operator of the San Martín Mine, reached an agreement with the El Doctor Agrarian Community, in the municipality of Cadereyta de Montes, Querétaro, Mexico, granting CMPB the social license to operate the La Tortilla Project ("La Tortilla").

This agreement is for the same 10-year period as the La Tortilla lease has with the concession owner, with an option to renew. The agreement grants CMPB permission to use the access road to La Tortilla, which passes through their communities. The agreement prioritizes the well-being of the communities and the stability and continued operation of La Tortilla.

The general terms of the agreement directly benefit the communities, creating well-paying jobs, contributing to the economic stability of local residents, improving basic medical services, and enhancing the community's quality of life and infrastructure. It also includes the future possibility for the community members to provide transportation services to CMPB, transporting ore from La Tortilla to the processing plant at San Martín.

This is highly relevant because the new Mexican Mining Law, in its edition of May 8, 2023, explicitly states that community consultations will be conducted prior to the granting of the mining concession and simultaneously with the consultation required for the Environmental Impact Assessment (MIA) already in process to be approved by the environmental authorities, SEMARNAT.

Salvador García, B. Eng., the Company's Director and Chief Operating Officer, is the Company's Qualified Person for the project as required by NI 43-101 and prepared the technical information contained in this press release.

About Starcore

Starcore International Mines is engaged in precious metals production with focus and experience in Mexico. The Company's base of producing assets includes its gold-producing San Martin Mine and the La Tortilla silver mine, both in the state of Querétaro, Mexico. The Company is a leader in Corporate Social Responsibility and advocates value driven decisions that will increase long term shareholder value. You can find more information on the investor friendly website here: www.starcore.com.

ON BEHALF OF STARCORE INTERNATIONAL MINES LTD

Signed "Robert Eadie"
Robert Eadie, Chief Executive Officer

LinkedIn
Twitter
Facebook

The Toronto Stock Exchange has not reviewed nor does it accept responsibility
for the adequacy or accuracy of this press release.

This news release contains "forward-looking" statements and information ("forward-looking statements"). All statements, other than statements of historical facts, included herein, including, without limitation, management's expectations and the potential of the Company's projects, are forward-looking statements. Forward-looking statements are based on the beliefs of Company management, as well as assumptions made by and information currently available to Company's management and reflect the beliefs, opinions, and projections on the date the statements are made. Forward-looking statements involve various risks and uncertainties and accordingly, readers are advised not to place undue reliance on forward-looking statements. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. The Company assumes no obligation to update forward‐looking statements or beliefs, opinions, projections or other factors, except as required by law.

NOT FOR DISTRIBUTION IN THE UNITED STATES

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/298845

Source: Starcore International Mines Ltd.

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Many of America’s Founding Fathers were also brewers. The Brewer Patriot Collection, originally available for a limited time in 2006, features founding-era beers based on original recipes of the time. The Collection includes: George Washington Porter, brewed from Washington’s original recipe as found in the New York Public Library; James Madison Dark Wheat Ale, based on notes from his brewing mentor Thomas Jefferson; 1790 Hard Root Beer, a re-creation of an authentic New England-style brew in honor of Samuel Adams (and his cousin John Adams, of course); and No. 3 Ginger Honey Ale, based on notes from some of the beers made by Jefferson. The “Raise a Sam” national campaign brings people together this summer with the goal of generating 250,000 cheers moments. Fans can follow @samueladamsbeer to learn more about upcoming sweepstakes, merch drops and sampling experiences where they can #RaiseASam.The Star Spangled Variety Pack debuts with Summer Ale, Porch Rocker, American Light and an exclusive Blueberry Lager in retro packaging. Boston, MA, May 28, 2026 (GLOBE NEWSWIRE) --

Samuel Adams, the American pioneer of craft beer that helped start the American craft beer revolution in 1984 when it declared independence from the boring beers of the 1980s, is celebrating America’s 250th by brewing the original recipes and brewing techniques of the Founding Fathers.

Brewer Patriot Collection: Samuel Adams is releasing the Brewer Patriot Collection from their vault. The bold, experimental limited-edition four-pack, originally produced for a limited time in 2006, recreated the beers poured in Colonial American taverns, based on the original recipes and the independent spirit of the Founding Fathers who brewed them: George Washington, James Madison, Thomas Jefferson and of course, Samuel Adams. The beers include George Washington Porter, James Madison Dark Wheat Ale, 1790 Hard Root Beer and No. 3 Ginger Honey Ale.

“Raise a Sam” All Summer Long: The Brewer Patriot Collection is one element of Samuel Adams’ “Raise a Sam” national campaign to bring drinkers together this summer with the goal of generating 250,000 cheers moments. The campaign features classic summer brews, limited-edition merchandise, brand activations at iconic American events, on-premise samplings, activities at local breweries and taprooms, and exclusive social engagement. Fans can participate using the rallying hashtag #RaiseASam, where they’ll have the chance to win $250 in beer money as a thank you.

Limited-Release Star Spangled Variety Pack: For drinkers seeking tried-and-true seasonal classics, Samuel Adams dropped the Star Spangled Variety Pack featuring four beloved summer brews in retro-inspired patriotic packaging: Summer Ale, Porch Rocker, American Light and an exclusive Blueberry Lager.

“The independent spirit that shaped America also fuels Samuel Adams,” said Jon London, senior director, head of beer, Boston Beer Company. “Renowned for challenging brewing conventions and advancing craft beer, we lead with a focus on quality, innovation and character. This historic summer, we invite drinkers to honor the past and raise a glass to the future.”

Brewer Patriot Collection Details
The Brewer Patriot Collection introduces founding-era brewing traditions to drinkers with an appetite for discovery. Fair warning: inspired by history's boldest brewers – George Washington, Thomas Jefferson, James Madison and Samuel Adams – these beers don't play it safe. Each of the four beers features unique, historically based ingredients and based on the original recipes that showcase how far the craft beer movement (and taste buds) have come.

The Collection is available now on GiveThemBeer.com for $17.76, while supplies last. 

George Washington Porter (ABV: 5.5%) Brew Story: George Washington loved Porters, so much so that he paved the way for American Porters and brewed his own recipes at-home, including one preserved in the New York Public Library.Flavor Notes: Toasted malt with notes of toffee, cocoa and dates with a more assertive hop finishSpecial Ingredients: Molasses and licoriceSuggested Food Pairings: Blackened fish, steak au poivre, gingerbread, bittersweet chocolate mousse   James Madison Dark Wheat Ale (ABV: 5.5%) Brew Story: James Madison was a dedicated homebrewer, mentored by Thomas Jefferson, and championed the establishment of a National Brewery - and boldly suggested a cabinet-level "Secretary of Beer.” Flavor Notes: Tart, sweet, subtle smoky finish with notes of cocoa and toffeeSpecial Ingredients: Smoked malted barley Suggested Food Pairings: Grilled chicken, salmon, swordfish, bread pudding 1790 Hard Root Beer (ABV: 5.5%) Brew Story: The Founding Fathers were innovative with local ingredients. This spicy and herbal brew is named after the year hard root beers became colonial tavern staples. It’s also the type of beer Samuel Adams, cousin to other Founding Father John Adams, would have brewed and enjoyed. Flavor Notes: Spicy, herbal notes of sassafras, wintergreen and licorice balanced with sweetnessSpecial Ingredients: Molasses, honey and vanilla Suggested Food Pairings: Fried chicken, clams, pizza, vanilla ice cream No. 3 Ginger Honey Ale (ABV: 5.5%) Brew Story: Ginger beer was a staple in colonial kitchens of the 1700s. Thomas Jefferson and his wife, Martha, kept multiple notes on their different brews and even brewed 15 gallons every two weeks at their Monticello estate.Flavor Notes: Bright, zesty with the floral sweetness of wildflower honey balanced by a subtle maltinessSpecial Ingredients: Ginger, lemon peel and honey Suggested Food Pairings: Glazed ham, Chinese spareribs, honey mustard chicken, baklava, lemon meringue pie  Limited-Release Star Spangled Variety Pack Details

For drinkers seeking tried-and-true seasonal classics, Samuel Adams dropped the Star Spangled Variety Pack featuring four beloved summer brews in retro-inspired patriotic packaging. Summer AlePorch RockerAmerican LightBlueberry Lager (exclusive to this pack) Availability & Pricing: 12-pack (SRP: $17.99) | 24-pack (SRP: $29.99) Available now at major U.S. retailers and samueladams.com/find-a-sam. Brand Activations at Premier Summer Events: Samuel Adams is activating at America's most iconic summer celebrations:

Sail Boston® as part of Sail250® (Boston, MA)Fourth at The Wharf  (Washington D.C.)Big Bite Tour  stops in Philadelphia, Chicago and more  Custom Merchandise: The brand is collaborating with Ebbets Field, the iconic heritage sportswear brand, to release limited-edition merchandise in celebration of America250. Follow @samueladamsbeer for updates.

How to Find a Sam Near You
Whether at the ballpark, backyard barbecue, or any moment in between – more Sam equals more fun. Find a Sam near you at samueladams.com/find-a-sam.

For more information, visit SamuelAdams.com or follow @SamuelAdamsBeer.

###
About Samuel Adams: The Beer
Samuel Adams is a leading independent, American craft brewer that helped to launch the craft beer revolution. The brewery began in 1984 when Founder and Brewer Jim Koch used a generations-old family recipe to brew beer in his kitchen. Inspired and unafraid to challenge conventional thinking about beer, Jim brought the recipe to life with hopes drinkers would appreciate the complex, full-flavor and started sampling the beer in Boston. He named the flagship brew Samuel Adams Boston Lager in recognition of one of our nation's founding fathers, a revolutionary man of independent and pioneering spirit. Today, Samuel Adams is one of the world's most awarded breweries and remains focused on crafting the highest quality beers through innovation and experimentation in the relentless pursuit of better. Samuel Adams remains dedicated to elevating and growing the American craft beer industry overall, including providing education and support for entrepreneurs and fellow brewers through its philanthropic program, Brewing the American Dream, which helps others pursue their American Dream. For more information, visit www.SamuelAdams.com or follow @SamuelAdamsBeer  

About The Boston Beer Company    
The Boston Beer Company, Inc. (NYSE: SAM) began in 1984 brewing Samuel Adams beer and has since grown to become one of the largest and most respected craft brewers in the United States. We consistently offer the highest-quality products to our drinkers, and we apply what we’ve learned from making great-tasting craft beer to making great-tasting and innovative “beyond beer” products. Boston Beer Company has pioneered not only craft beer but also hard cider, hard seltzer, and hard tea. Our core brands include household names like Angry Orchard Hard Cider, Dogfish Head, Samuel Adams, Sun Cruiser, Truly Hard Seltzer, and Twisted Tea Hard Iced Tea. We have taprooms and hospitality locations in Delaware, Massachusetts, New York, and Ohio. For more information, please visit our website at www.bostonbeer.com, which includes links to our respective brand websites.

Samuel Adams Brewer Patriot Collection

Samuel Adams Brewer Patriot Collection Samuel Adams launches the Brewer Patriot Collection which includes the George Washington Porter, Jam...

BOSTON, June 04, 2026 (GLOBE NEWSWIRE) -- Sun Cruiser, the fast-growing ready-to-drink spirits brand and Official Ready-to-Drink Cocktail of the U.S. Open and U.S. Women’s Open presented by Ally, is teaming up with luxury golf lifestyle brand G/FORE on a limited-edition 17-piece collection dropping today. Where premium sport meets old-school, outdoor fun, this collection mixes G/FORE’s bold, colorful style with the easygoing energy that Sun Cruiser fans bring to the course.

The Sun Cruiser x G/FORE collection spans apparel and accessories for men and women – from polos, quarter‑zips and hoodies to hats, bags, golf gloves, and more. Inspired by what Sun Cruiser does best: premium quality, easygoing energy, and time in the sunshine, each piece is designed to carry the Sun Cruiser vibe from the first tee to the 19th hole. Shop the full collection exclusively on Sun Cruiser’s e-store.

“Sun Cruiser is a go-to for our fans when they’re heading out for a day on the golf course, so we wanted to make sure they look great while they’re out there by partnering with one of the biggest names in golf apparel,” said Erica Taylor, senior brand director for Sun Cruiser. “G/FORE brings the same effortless quality and laid-back energy our drinkers love, and this collection is sure to elevate their style on and off the course.”

“We’re excited to be partnering with Sun Cruiser for their bespoke collection. Their laidback and vibrant aesthetic meshes perfectly with our summer-ready designs. We can’t wait to see fans in these styles on the course and beyond,” said Sabina Wood, director of creative marketing at G/FORE.

And no 19th hole look is complete without a Sun Cruiser in hand. Crafted with premium vodka and real ingredients, Sun Cruiser’s lineup of ready-to-drink iced teas and lemonades is made with no bubbles for smooth, all-day sipping. At 100 calories, 1g of sugar, and 4.5% ABV, it’s perfectly balanced and refreshing, making it an easy choice for any moment in the sun. It’s built for the course, now with the gear to match.

For more on Sun Cruiser, follow along on social @DrinkSunCruiser and visit us at drinksuncruiser.com.

About Sun Cruiser

Made for those who enjoy the sun on their face and hanging outdoors with friends, Sun Cruiser Iced Tea & Vodka and Sun Cruiser Lemonade & Vodka are made with real ingredients and premium vodka for a perfect choice to sip and share. At just 100 calories, 4.5% ABV per 12 oz serving, 1 gram of sugar, and no bubbles to weigh you down, Sun Cruiser has just a kiss of sweetness and tastes refreshingly smooth in a mix of delicious flavors. Drinkers can enjoy a variety of Sun Cruiser flavors, including Classic Iced Tea, Peach Iced Tea, Raspberry Iced Tea, Half & Half, Lemonade, Pink Lemonade, Strawberry Lemonade, Blueberry Lemonade, and the new White Tea.  For more information, follow along on social @DrinkSunCruiser and visit us at drinksuncruiser.com.

About The Boston Beer Company

The Boston Beer Company, Inc. (NYSE: SAM) began in 1984 brewing Samuel Adams beer and has since grown to become one of the largest and most respected craft brewers in the United States. We consistently offer the highest-quality products to our drinkers, and we apply what we’ve learned from making great-tasting craft beer to making great-tasting and innovative “beyond beer” products. Boston Beer Company has pioneered not only craft beer but also hard cider, hard seltzer, and hard tea. Our core brands include household names like Angry Orchard Hard Cider, Dogfish Head, Samuel Adams, Sun Cruiser, Truly Hard Seltzer, and Twisted Tea Hard Iced Tea. We have taprooms and hospitality locations in Delaware, Massachusetts, New York, and Ohio. For more information, please visit our website at www.bostonbeer.com.

About G/FORE

G/FORE was conceptualized with a passion for modern design combined with a love of golf. Inspired by art, architecture, and high fashion, the brand is distinguished by their attention to detail, sophisticated ease, whimsical nature, youthful energy, and sense of humor. Consistently striving to make a powerful and colorful impact on their favorite game, the brand intends to disrupt the industry while honoring the sport and its rich traditions.

Founded in 2011, G/FORE has established itself as a leader and innovator in golf fashion with a wide range of premium footwear, apparel, and accessories for both men and women. They have gained the attention and adoration of golf enthusiasts across the globe as well as well-known tour players like Brandt Snedeker, Ryann O’Toole, Alvaro Quiros, and more.

G/FORE products can be found online at gfore.com along with specialty retailers and top golf pro shops in 35+ countries.

Sun Cruiser and G/FORE Elevate Golf Course Style with New Limited-Edition Apparel Collection Sun Cruiser and G/FORE Elevate Golf Course Style with New Limited-Edition Apparel Collection

Sun Cruiser and G/FORE Elevate Golf Course Style with New Limited-Edition Apparel Collection Sun Cruiser partners with luxury golf lifestyle brand on a collaboration built for golfers to cruise... Sun Cruiser and G/FORE Elevate Golf Course Style with New Limited-Edition Apparel Collection Sun Cruiser partners with luxury golf lifestyle brand on a collaboration built for golfers to cruise...

It has been about a month since the last earnings report for Boston Scientific (BSX - Free Report) . Shares have lost about 13% in that time frame, underperforming the S&P 500.

But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Boston Scientific due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.

BSX Q1 Earnings Match, '26 View DownBoston Scientific Corporation (BSX - Free Report) posted first-quarter 2026 adjusted earnings per share (EPS) of 80 cents, up 6.7% from the year-ago figure. The figure matched the Zacks Consensus Estimate. 

The quarter’s adjustments included certain amortization expenses, litigation-related net charges and restructuring charges, among others. Reported EPS for the first quarter was 90 cents compared with the year-ago quarter’s 45 cents.

Revenue Details of BSXFirst-quarter revenues totaled $5.20 billion, up 11.6% year over year on a reported basis and up 9.4% on an operational and organic basis. The top line exceeded the Zacks Consensus Estimate by 0.4%. 

BSX's Q1 Revenues by RegionsIn the first quarter, revenues rose 10.9% in the United States on a reported basis (same operationally).

Reported revenues increased 10.1% in EMEA, or 1.2% on an operational basis, and 14.7% in Asia Pacific, or 12% operationally.

Reported revenues increased 19% in Latin America and Canada (up 12% operationally). 

Breaking Down BSX's Q1 Revenues by SegmentsBoston Scientific recently reorganized its operational structure and aggregated its core businesses into two reportable segments — MedSurg and Cardiovascular. Both these segments generate revenues from the sale of Medical Devices.

MedSurg

MedSurg revenues in the first quarter totaled $1.70 billion, up 7.8% year over year on a reported basis (up 5.7% on an operational and organic basis).

Within this, the Endoscopy unit generated revenues of $736 million, up 6.8% organically and operationally.

Urology revenues amounted to $646 million, reflecting organic and operational growth of 0.5%.

The Neuromodulation business reported $318 million in revenues, reflecting 15.4% year-over-year organic and operational growth.

Cardiovascular

The company generates maximum revenues from this segment. Revenues in the first quarter totaled $3.50 billion, up 13.5% (reportedly) and 11.2% (organically and operationally) year over year.

BSX’s Margin Performance in Q1The gross margin expanded 60 basis points (bps) year over year to 69.4%. There was a 9.4% rise in the cost of products sold (to $1.59 billion) in the reported quarter.

Selling, general and administrative expenses rose 11.5% to $1.78 billion. Research and development expenses rose 16.5% to $516 million. Royalty expenses of $12 million declined 14.3% year over year. Adjusted operating margin expanded 27 bps to 25.1%.

BSX’s Lowered 2026 and Q2 ViewFor 2026, Boston Scientific now anticipates net sales to grow approximately 7-8.5% on a reported basis and 6.5-8% on an organic basis (down from previous growth guidance of 10.5-11.5% on a reported basis and 10-11% on an organic basis). The Zacks Consensus Estimate is currently pegged at $22.27 billion, indicating a 10.9% rise from the 2025 figure.

Full-year adjusted EPS is now expected in the range of $3.34-$3.41 (down from $3.43-$3.49). The Zacks Consensus Estimate is currently pegged at $3.45.

For the second quarter of 2026, revenue growth is projected in the range of approximately 5.5-7.5% on a reported basis (up 5-7% organically). Adjusted earnings are expected to be in the range of 82-84 cents per share.

The Zacks Consensus Estimate for second-quarter earnings and revenues is pegged at 86 cents per share and $5.57 billion, respectively.

How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a downward trend in estimates review.

VGM ScoresAt this time, Boston Scientific has a average Growth Score of C, though it is lagging a bit on the Momentum Score front with a D. Charting a somewhat similar path, the stock was allocated a score of C on the value side, putting it in the middle 20% for value investors.

Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Boston Scientific has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.

TORONTO, May 26, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (“Belo Sun” or the “Company”) (TSX:BSX OTCQX:BSXGF) today is pleased to announce that each of the six individuals nominated for election as a director of Belo Sun at the Company's Annual and Special Meeting of Shareholders held on May 26, 2026 (the “Meeting”), was elected.

It's commonplace for companies in the healthcare space to buy their way into new markets and product categories. Boston Scientific (BSX 0.32%), a top healthcare stock and medical device company, recently announced it was investing $1.5 billion in MiRus LLC for an approximate 34% stake in the business.

The investment gives Boston Scientific a foothold in the transcatheter aortic valve replacement (TAVR) market, which Grand View Research estimates could grow from $4.5 billion in 2024 to $12.2 billion by 2033. The announcement happened a week ago, and thus far, Wall Street isn't showing any loss of love for the stock. Of 36 analysts polled by CNN Business, 92% have rated Boston Scientific a buy.

Here's more about Boston Scientific's investment, and what it could mean for investors.

Image source: Getty Images.

The fine print reveals that an even bigger transaction could be lurking Transcatheter aortic valve replacement is a treatment for aortic valves in the human heart that are too narrow to open properly. MiRus is developing the proprietary Siegel TAVR system; it's the first nickel-free, balloon-expandable TAVR valve intended to restore function and normal blood flow to severely narrowed aortic valves.

Boston Scientific will immediately own about a third of the company with this initial investment, but the deal also lays the groundwork for a potential 100% acquisition. If the MiRus TAVR system meets the appropriate milestones, Boston Scientific has the option to pay up to an additional $3 billion to acquire it.

It's a clever deal because it paves the way for the acquisition without risking the full amount should the system ultimately fail. The only real downside is that it won't contribute anything to Boston Scientific's earnings in 2026, so there's no immediate return on that capital.

Today's Change

(

-0.32

%) $

-0.15

Current Price

$

47.02

Wall Street could be following the insiders Sure, 92% of analysts on CNN Business rate Boston Scientific as a buy, but that alone shouldn't be a reason for an individual investor to buy a stock. It does help the case when insiders, key employees at the company, begin scooping up shares. Regulatory filings on May 21 revealed that three directors at the company recently purchased shares worth a total of over half a million dollars.

Additionally, Boston Scientific recently announced a $2 billion accelerated buyback program, in which it purchases its own shares on the open market ahead of its previously announced schedule. It's a pretty loud signal that management views the stock's valuation favorably.

Wall Street analysts estimate that Boston Scientific will grow earnings by over 16% annually over the next three to five years. The stock is currently a bargain, trading at just 17 times 2026 earnings estimates, assuming earnings grow at or near that pace.

Boston Scientific had already laid the groundwork for growth and was a compelling buy last week. Now, the future could be even brighter, with a groundbreaking new product potentially opening a massive new market for the company.

Butterfield Announces Agreement to Acquire Control of CIBC Caribbean in $1.8 Billion Transaction The Bank of N.T. Butterfield & Son Limited (“Butterfield”) (NYSE: NTB | BSX: NTB.BH) has entered into a definitive agreement to acquire CIBC’s 91.7% interest in CIBC Caribbean Bank Limited (“CIBC Caribbean”), a relationship bank with a longstanding history serving communities across the Caribbean, to create a leading banking and wealth management platform in international financial centers and attractive Caribbean markets, with approximately $29 billion in assets. The transaction brings together two complementary banks with deep roots and established relationships across their combined footprint with heightened capacity, greater diversification and scalable growth to drive long-term value for all stakeholders.

Butterfield and CIBC Caribbean’s expanded capabilities and scale are expected to provide enhanced corporate, personal and wealth management services across their combined client bases. Clients can expect greater ability to process cross-border payments, increased consumer and merchant banking capabilities, and continued investments in technology and digital banking infrastructure. Butterfield will maintain both organizations’ operational footprints, including CIBC Caribbean’s regional headquarters in Barbados, ensuring continuity for customers and employees. Butterfield is also committed to its and CIBC Caribbean’s philanthropic, financial education, and sustainability initiatives in each of their geographies, which will continue to provide outsized, tangible and mutually beneficial financial impacts for the combined company and its communities.

Michael Collins, Butterfield’s Chairman and Chief Executive Officer, said: “Since Butterfield’s 2016 listing on the NYSE, we have successfully grown and enhanced profitability through bank and trust acquisitions. This deal combines two storied and complementary banks, with significant local scale advantages and time-honored customer relationships in their respective core jurisdictions. The transaction will offer both scale and diversification to the benefit of all stakeholders, positioning Butterfield as a leading independent bank and wealth manager operating across international financial centers and attractive Caribbean markets. I look forward to welcoming our talented new colleagues and valued clients.”

Mark St. Hill, Chief Executive Officer of CIBC Caribbean, added:“For our clients, employees and communities, this combination brings together two organizations with shared values and a common focus on relationship banking, innovating and community impact. We look forward to building on our legacy as the region’s champion in financial services.”

Harry Culham, President and CEO, CIBC, commented:"The entire CIBC Caribbean team led by Mark St. Hill has built a strong, client-focused bank across the region, and we look forward to realizing the strategic benefits of this transaction to deliver more for all stakeholders.”

Transaction Details

The total consideration to be paid for CIBC Caribbean will be comprised of $1,091 million in cash and $703 million in Butterfield shares valued by reference to Butterfield’s 10-day NYSE VWAP of $55.66 as of May 27, 2026, for an aggregate purchase price of $1,794 million, or $1.14 per CIBC Caribbean share.

Under the terms of the agreement, which have been unanimously approved by the Board of Directors of Butterfield, Butterfield will acquire CIBC Investments (Cayman) Limited, the holding company for CIBC’s 91.7% interest in CIBC Caribbean. Butterfield will subsequently commence a mandatory take-over bid for the remaining 8.3% of total outstanding shares of CIBC Caribbean held by minority shareholders, with the objective of acquiring full ownership of CIBC Caribbean, subject to applicable law and regulatory requirements.

CIBC Caribbean’s minority shareholders will be offered equivalent economic terms as CIBC, and will also have the option to elect to receive up to 100% of their consideration in Butterfield shares, providing them with the opportunity to maintain the entirety of their investment in the combined organization, should they choose to do so. Houlihan Lokey, acting as financial advisor to the Special Committee of CIBC Caribbean’s Board of Directors, has provided an opinion to the Special Committee with respect to the fairness from a financial point of view of the consideration to be offered to CIBC Caribbean’s minority shareholders in the mandatory take-over bid. Assuming minority shareholders elect the same mix of cash and shares as CIBC, following completion of the take-over bid they would collectively own approximately 2% of Butterfield.

In connection with the transaction, Butterfield has obtained commitments for $700 million of Tier 2 capital-qualifying subordinated debt financing expected to be raised prior to closing. Following completion of the transaction, the combined company is expected to maintain capital levels significantly above applicable regulatory thresholds on a consolidated basis, with a pro forma Common Equity Tier 1 (CET1) ratio above 12%, and total capital above 19% at closing.

The transaction is expected to close in the first half of 2027, subject to receipt of Butterfield shareholder and regulatory approvals and the satisfaction of customary closing conditions. Following the transaction, Butterfield’s ordinary shares will continue to be listed on the New York Stock Exchange (NYSE) and the Bermuda Stock Exchange (BSX), and Butterfield intends to undertake additional secondary share listings on the Barbados Stock Exchange (BSE), the Bahamas International Securities Exchange (BISX), and the Trinidad & Tobago Stock Exchange (TTSE), subject to local listing and regulatory requirements.

Following completion of the transaction, CIBC will own an approximately 22% stake in the combined entity. Under the terms of Butterfield and CIBC’s shareholder agreement, CIBC will then initially have the right to appoint two directors to Butterfield’s Board. The shareholder agreement will also provide for certain lockup restrictions with respect to CIBC’s stake in Butterfield, and include customary standstill obligations and registration rights.

The Bermuda Monetary Authority (BMA) will continue to serve as the consolidated regulatory supervisor of Butterfield across all of its locations. Butterfield will also collaborate with all relevant jurisdictional authorities to ensure continuity, market confidence, and access to high-quality financial services within each jurisdiction.

Financial Highlights

Total purchase price of $1,794 million, or $1.14 per CIBC Caribbean share, representing 106% of CIBC Caribbean’s tangible book value as of January 31, 2026 Consideration is 61% cash ($1,091 million) and 39% ($703 million) Butterfield shares Consideration per CIBC Caribbean share of $0.6918 in cash and 0.008008 in Butterfield shares based on the 10-day NYSE VWAP of $55.66 as of May 27, 2026 Butterfield has obtained commitments for $700 million of Tier 2 capital-qualifying subordinated debt financing Pro forma Common Equity Tier 1 (CET1) ratio above 12%, and total capital above 19% at closing 12% expected accretion to GAAP EPS in year 1 with fully phased-in synergies, excluding integration costs 15% expected accretion to cash EPS in year 1 with fully phased-in synergies, excluding integration costs, rate marks and transaction-related amortization 10% expected accretion to Butterfield’s tangible book value per share Internal rate of return of 20%+ Pre-tax cost savings expected to reach an annual run rate of approximately $49 million once fully phased in by 2030 Advisors

Barclays is serving as lead financial advisor to Butterfield, and Sullivan & Cromwell, Carey Olsen and Lex Caribbean are serving as legal advisors. BofA Securities is serving as financial advisor to Butterfield’s Board of Directors.

H/Advisors is serving as communications advisor to Butterfield.

Wachtell, Lipton, Rosen & Katz, Torys LLP and Chancery Chambers are serving as legal advisors to CIBC.

CIBC Capital Markets is serving as financial advisor to CIBC Caribbean, and Mayer Brown LLP is serving as legal advisor. Houlihan Lokey is serving as financial advisor to the Special Committee of CIBC Caribbean’s Board of Directors.

Finer Points Consultants is serving as communications advisor to CIBC Caribbean.

Investor Call

Butterfield will host a conference call for investors and analysts on Thursday, May 28, 2026 at 8:15 a.m. Eastern Time to discuss the transaction.

Dial-in information: +1 (844) 855 9501 (toll-free US) or +1 (412) 858 4603 (international)
Conference ID: Butterfield Group

Live audio webcast: A live audio webcast of the call can be accessed via Butterfield’s investor relations page on Butterfield’s website at https://www.butterfieldgroup.com/investor-relations/events-presentations

Replay: An audio replay of the call will be available at https://www.butterfieldgroup.com/investor-relations/events-presentations

Website

You can also learn more about today’s announcement at https://www.butterfieldgroup.com/future

Forward-Looking Statements

Certain of the statements made in this press release are forward-looking statements within the meaning of, and subject to the protections of, Section 27A of the Securities Act, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are not historical facts and include statements with respect to, among other things, our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions, and future performance, including, without limitation, statements regarding the proposed acquisition of CIBC Caribbean by Butterfield; the expected timing, structure, terms and completion of the proposed transaction; the expected form and mix of consideration, including the issuance of Butterfield ordinary shares; any acquisition of shares from minority shareholders of CIBC Caribbean or related compulsory acquisition, squeeze-out or similar process; the expected ownership, governance, management, capital, regulatory and operating profile of Butterfield following the proposed transaction; the expected financing of the proposed transaction, including the amount, terms and timing of the proposed subordinated debt financing; and the anticipated benefits of the proposed transaction, including expected scale, diversification, cost savings, synergies, earnings accretion, tangible book value per share accretion, capital generation, regulatory capital ratios, risk-weighted assets, liquidity, deposit mix, market position and other financial and operating impacts.

Forward-looking statements involve known and unknown risks, uncertainties and other factors, many of which are beyond Butterfield’s control, which may cause the actual results, performance, capital, ownership, financial condition or achievements of Butterfield to be materially different from future results, performance, capital, ownership, financial condition or achievements expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Butterfield’s ability to successfully complete the proposed acquisition of CIBC Caribbean on the anticipated terms or timeline or at all; Butterfield’s ability to realize the anticipated benefits of the proposed transaction in the expected timeframes or at all, including cost savings, synergies, capital and balance sheet optimization initiatives, earnings accretion, and tangible book value per share accretion; Butterfield’s ability to successfully integrate CIBC Caribbean’s businesses, operations, systems, controls, compliance programs, risk management framework, personnel and culture into those of Butterfield; the risk that such integration may be more difficult, time-consuming or costly than expected; the failure of any of the conditions to the proposed transaction to be satisfied or waived; the failure to obtain required shareholder, regulatory, governmental, securities exchange, exchange-control or other approvals, or delays in obtaining such approvals; the risk that such approvals may result in the imposition of conditions, restrictions or requirements that could adversely affect Butterfield, CIBC Caribbean or the expected benefits of the proposed transaction potentially materially or that any proposed conditions, restrictions or requirements or other actions of regulatory or governmental bodies or securities exchanges could delay or prevent the closing of the proposed transactions; the risk that any minority shareholder offer, compulsory acquisition, squeeze-out or similar process is delayed, not completed or completed on different terms than expected; revenues following the proposed transaction being lower than expected; operating costs, customer loss and business disruption, including difficulties in maintaining relationships with employees, customers, clients, depositors, vendors, suppliers, regulators and other business partners, being greater than expected; risks associated with the disruption of management’s attention from Butterfield’s ongoing business operations due to the proposed transaction; reputational risks and potential adverse reactions to the announcement, pendency or completion of the proposed transaction; the outcome of any legal, regulatory or shareholder proceedings, inquiries or investigations that may be instituted or arise in connection with the proposed transaction; the possibility that the proposed transaction may be more expensive to complete than anticipated, including as a result of unexpected transaction, integration, restructuring, financing, litigation, regulatory, tax, accounting or other costs; dilution caused by the issuance of additional Butterfield ordinary shares in connection with the proposed transaction; changes in Butterfield’s share price, interest rates, foreign exchange rates, capital markets or other market conditions that may affect the transaction financing or expected financial impacts of the proposed transaction; the risk that any subordinated debt or other transaction financing is not obtained on the expected terms, timing or at all; and the risk that assumptions underlying pro forma financial information, purchase accounting, credit marks, fair value marks, integration costs, cost savings, synergies, capital ratios, earnings accretion, tangible book value per share accretion, return metrics and other financial impacts prove to be inaccurate.

Other factors that may impact Butterfield’s future results, performance, financial condition or achievements include worldwide and regional economic conditions, including economic growth and general business conditions in Bermuda, the Cayman Islands, Barbados, The Bahamas, Turks and Caicos, Trinidad and Tobago, the broader Atlantic, Caribbean and other markets in which Butterfield or CIBC Caribbean operates; fluctuations in interest rates, inflation, monetary policy, foreign exchange rates, capital markets, tourism, real estate markets and sovereign credit ratings, including a decline in Bermuda’s sovereign credit rating; any sudden liquidity crisis; changes in customer behavior, including customer borrowing, repayment, investment and deposit practices; unfavorable developments concerning asset quality, credit quality, loan losses, non-performing loans, collateral values, loan concentrations, sovereign exposures, residential mortgage risk weighting, reserves, funding costs, liquidity and deposit flows; competitive product and pricing pressures; security risks, including cybersecurity, data privacy, fraud, financial crime, anti-money laundering and sanctions risks; the impact, extent and timing of technological changes, systems conversions and operational resilience initiatives; risks relating to the success of Butterfield’s updated systems and platforms; capital management activities; changes in laws, regulations, accounting standards, tax laws, regulatory capital or liquidity requirements and supervisory expectations; potential impacts of climate change, hurricanes and other natural disasters; compliance with regulatory requirements; and other factors.

Forward-looking statements can be identified by words such as "anticipate," "assume," "believe," "estimate," "expect," "indicate," "intend," "may," "plan," "point to," "predict," "project," "seek," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions, although not all forward-looking statements contain these identifying words. All statements other than statements of historical fact are statements that could be forward-looking statements.

All forward-looking statements in this disclosure are expressly qualified in their entirety by this cautionary notice, including, without limitation, those risks and uncertainties described in our SEC reports and filings, including under the caption "Risk Factors" in our most recent Annual Report on Form 20-F and in any subsequent reports furnished or filed with the Securities and Exchange Commission ("SEC"). Such reports are available upon request from Butterfield, or from the SEC including through the SEC’s website at https://www.sec.gov. Any forward-looking statements made by Butterfield are current views as at the date they are made. Except as otherwise required by law, Butterfield assumes no obligation and does not undertake to review, update, revise or correct any of the forward-looking statements included in this disclosure, whether as a result of new information, future events or other developments. You are cautioned not to place undue reliance on the forward-looking statements made by Butterfield in this disclosure. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, and should only be viewed as historical data.

About Butterfield:

Butterfield is a full-service bank and wealth manager headquartered in Hamilton, Bermuda, providing services to clients from Bermuda, the Cayman Islands, Guernsey and Jersey, where our principal banking operations are located, and The Bahamas, Switzerland, Singapore and the United Kingdom, where we offer specialized financial services. Banking services comprise deposit, cash management and lending solutions for individual, business and institutional clients. Wealth management services are composed of trust, private banking, asset management and custody. In Bermuda, the Cayman Islands and Guernsey, we offer both banking and wealth management. In The Bahamas, Singapore and Switzerland, we offer select wealth management services. In the UK, we offer residential property lending. In Jersey, we offer select banking and wealth management services. Butterfield is publicly traded on the New York Stock Exchange (symbol: NTB) and the Bermuda Stock Exchange (symbol: NTB.BH). Further details on the Butterfield Group can be obtained from our website at: www.butterfieldgroup.com.

About CIBC Caribbean:

CIBC Caribbean is a relationship bank offering a full range of market leading financial services through our Corporate Banking, Personal and Business Banking and Private Wealth segments. CIBC Caribbean is located in ten (10) countries around the Caribbean, providing banking services through approximately 2,700 employees in 41 branches and offices. CIBC Caribbean also has a representative office in Hong Kong that provides business development and relationship management for its fund administration business.

About CIBC:

CIBC is a leading North American financial institution with 15 million personal banking, business, public sector and institutional clients. Across Personal and Business Banking, Commercial Banking and Wealth Management, and Capital Markets, CIBC offers a full range of advice, solutions and services through its leading digital banking network, and locations across Canada, in the United States and around the world.

BF-All

View source version on businesswire.com: https://www.businesswire.com/news/home/20260528619464/en/

Boston Scientific (BSX - Free Report) ended the recent trading session at $49.11, demonstrating a -2.68% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 0.58%. Meanwhile, the Dow gained 0.05%, and the Nasdaq, a tech-heavy index, added 0.91%.

The medical device manufacturer's stock has dropped by 11.71% in the past month, falling short of the Medical sector's gain of 2.82% and the S&P 500's gain of 4.96%.

The investment community will be closely monitoring the performance of Boston Scientific in its forthcoming earnings report. On that day, Boston Scientific is projected to report earnings of $0.84 per share, which would represent year-over-year growth of 12%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $5.41 billion, up 6.82% from the year-ago period.

BSX's full-year Zacks Consensus Estimates are calling for earnings of $3.37 per share and revenue of $21.67 billion. These results would represent year-over-year changes of +10.13% and +7.95%, respectively.

It's also important for investors to be aware of any recent modifications to analyst estimates for Boston Scientific. These recent revisions tend to reflect the evolving nature of short-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.09% decrease. At present, Boston Scientific boasts a Zacks Rank of #4 (Sell).

In terms of valuation, Boston Scientific is presently being traded at a Forward P/E ratio of 14.96. This valuation marks a discount compared to its industry average Forward P/E of 18.52.

We can also see that BSX currently has a PEG ratio of 0.93. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. By the end of yesterday's trading, the Medical - Products industry had an average PEG ratio of 1.52.

The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 155, putting it in the bottom 37% of all 250+ industries.

The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.

Key Takeaways Boston Scientific posted 11.6% sales growth, led by WATCHMAN and FARAPULSE demand. Abbott completed the Exact Sciences acquisition, expanding its cancer diagnostics business. BSX carries a higher analyst upside target, while ABT trades at a lower forward P/S multiple. In the past year, shares of Boston Scientific (BSX - Free Report) and Abbott Laboratories (ABT - Free Report) have lost 53% and 35%, respectively, significantly underperforming the S&P 500’s 31.4% gain. U.S. medical stocks are facing pressure in 2026 due to restrictive regulatory changes, lower-than-expected government reimbursement rates and evolving healthcare policies.

Despite these hurdles, both Boston Scientific and Medtronic delivered robust first-quarter 2026 financial results. It is time for investors to assess whether this momentum can extend through 2026. Let’s find out.

Image Source: Zacks Investment Research

The Case for BSXBoston Scientific reported strong sales growth of 11.6% on a reported basis, exceeding the company’s guidance of 10.5% to 12.0%. Across its key business segments, MedSurg delivered net sales growth of 7.8%, while Cardiovascular grew 13.5%. The company continued to see strong demand for its WATCHMAN left atrial appendage closure (LAAC) platform and FARAPULSE pulsed field ablation (PFA) platform, which remained key growth drivers during the quarter.

During the quarter, Boston Scientific dealt with multiple operational challenges that led management to reduce full-year guidance. In the WATCHMAN franchise, stand-alone procedure volumes weakened amid hospital capacity limitations, reimbursement changes, workflow disruptions and an increasing shift toward concomitant procedures. The company’s EP segment also experienced heightened competitive intensity, contributing to larger-than-anticipated market-share losses, especially in the U.S. market. 

Within Urology, the stone business was affected by China’s volume-based procurement (VBP) program and product gaps in the core portfolio. The company also highlighted supply-chain disruptions in Endoscopy, inventory charges related to the discontinuation of the POLARx cryoablation system and discontinuation of the ACURATE platform, which mainly affected the EMEA region. 

Boston Scientific also noted the impact of the Middle East conflict on its Cardiac Rhythm Management business. Overall, management acknowledged that 2026 has become a more challenging year than initially anticipated due to these operational, competitive, and macroeconomic pressures.

The Case for ABTAbbott reported first-quarter sales growth of 7.8% on a reported basis. The quarter also marked a significant strategic milestone with its acquisition of Exact Sciences. The deal adds a high-growth business to Abbott’s portfolio, strengthening its leadership position in Diagnostics while expanding its presence in the rapidly growing cancer-diagnostics market.

Abbott also advanced several initiatives within its Medical Devices pipeline during the quarter. The company received earlier-than-expected regulatory approval and launched two new PFA catheters. It completed patient enrollment for its Catalyst left atrial appendage device trial and began development activities for an implantable extravascular ICD product.

Pressure persisted within Abbott’s Core Laboratory Diagnostics business because of China’s volume-based procurement (VBP) program and ongoing COVID-related disruptions. Although the Chinese market has started to stabilize, pricing compression and volume pressure linked to VBP continue to weigh on the business.

Abbott implemented strategic pricing actions in late 2025 to improve competitiveness and support volume recovery within the Nutrition business. Per the latest update, the business is still in an early recovery phase and requires further execution and new product launches to return to stronger growth. Within the Diabetes Care segment, continuous glucose monitoring (CGM) growth was affected by delays in the renewal process for an international tender, as well as challenging year-over-year comparisons tied to inventory restocking activity in the prior-year period.

Abbott identified macroeconomic and geopolitical uncertainty as ongoing risk factors. The company is monitoring potential impacts from the Middle East conflict, including pressure on freight availability, shipping logistics, oil and resin costs, and broader supply-chain disruptions. Although the direct financial impact remained limited during the first quarter, Abbott noted operational challenges related to ensuring timely product deliveries into affected regions.

Valuation: BSX vs. ABTBoston Scientific currently trades at a forward, one-year, price-to-sales (P/S) of 3.25X, lower than its median. Abbott’s 2.87X P/S also sits below its median. Abbott trades cheaper than Boston Scientific.

Image Source: Zacks Investment Research

Short Term Price Target Favors BSX Over ABTBSX: Based on short-term price targets offered by 28 analysts, the average price target of $84.25 represents an increase of 66.96% from the last closing price.

Image Source: Zacks Investment Research

ABT: Based on short-term price targets offered by 24 analysts, the average price target of $ 119.00 represents an increase of 38.89% from the last closing price.

Image Source: Zacks Investment Research

End NoteBoston Scientific delivered strong quarterly growth, supported by robust demand for its WATCHMAN and FARAPULSE platforms. However, the company faced several headwinds during the quarter, prompting management to lower its full-year outlook.

Abbott also reported solid first-quarter growth, driven by the acquisition of Exact Sciences and continued progress across its Medical Devices pipeline. Despite these positives, the company continued to face pressure from ongoing macroeconomic and geopolitical uncertainties, including supply-chain and logistics risks linked to the Middle East conflict.

Both BSX and ABT currently carry a Zacks Rank #4 (Sell), suggesting that existing shareholders may want to consider reducing or exiting their positions. However, based on valuation and one-year stock-price performance, ABT appears better positioned than BSX at current levels.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

TORONTO, June 01, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (TSX: BSX) (OTC: BSXGF) (the “Company” or “Belo Sun”) provides the following updates regarding a recent petition filed by the Brazilian Federal Prosecution Service (“MPF”) in civil public action No. 1002764-28.2025.4.01.3903 before the Federal Court of Altamira, Pará, Brazil.

Boston Scientific (BSX - Free Report) ended the recent trading session at $48.85, demonstrating a +2.43% change from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily gain of 0.41%. Meanwhile, the Dow gained 1.73%, and the Nasdaq, a tech-heavy index, lost 0.09%.

Prior to today's trading, shares of the medical device manufacturer had lost 14.84% lagged the Medical sector's gain of 0.14% and the S&P 500's gain of 4.59%.

Investors will be eagerly watching for the performance of Boston Scientific in its upcoming earnings disclosure. The company is expected to report EPS of $0.83, up 10.67% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $5.4 billion, up 6.63% from the year-ago period.

For the full year, the Zacks Consensus Estimates are projecting earnings of $3.37 per share and revenue of $21.64 billion, which would represent changes of +10.13% and +7.81%, respectively, from the prior year.

Investors should also pay attention to any latest changes in analyst estimates for Boston Scientific. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.

Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.22% lower within the past month. Boston Scientific presently features a Zacks Rank of #4 (Sell).

Digging into valuation, Boston Scientific currently has a Forward P/E ratio of 14.16. For comparison, its industry has an average Forward P/E of 16.76, which means Boston Scientific is trading at a discount to the group.

We can also see that BSX currently has a PEG ratio of 0.89. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As the market closed yesterday, the Medical - Products industry was having an average PEG ratio of 1.45.

The Medical - Products industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 160, finds itself in the bottom 35% echelons of all 250+ industries.

The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.

1.16K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Disclaimer: All research, figures, and interpretation are provided on a best-effort basis only and may be subject to error. Any view, opinion, or analysis does not constitute as investment or trading advice; please do your own due diligence.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Axsome Therapeutics, Inc. is rated Hold, as revenue growth and pipeline promise are offset by sequential declines and ongoing losses. AXSM's Q1 revenues grew 57% year-on-year to $191m, but both Auvelity and Sunosi saw sequential sales declines. Management's peak revenue targets—over $18bn across the portfolio—appear highly ambitious given current product performance and competitive dynamics.

Axsome Therapeutics, Inc. (AXSM) Q1 2026 Earnings Call Transcript

Smaller biotech stocks often fly under the radar. Many of them aren't consistently profitable, but some can deliver outsize growth for investors.

Axsome Therapeutics (AXSM +1.24%) is a mid-cap with only three approved therapies, while small-cap stock NovoCure (NVCR +0.45%) has approvals in four indications for its Tumor Treating Fields, and small-cap MBX Biosciences (MBX 5.97%) has several late-stage therapies in its pipeline. I like their potential and believe the markets haven't fully digested recent positive news for the trio.

Here's why I think each of these stocks could soar in 2026.

Image source: Getty Images.

Auvelity is bankrolling Axsome's pipeline progress Axsome just got great news that should help its bottom line. On May 1, the U.S. Food and Drug Administration (FDA) approved Axsome's drug Auvelity for a second major indication: Treating agitation associated with Alzheimer's disease. While Auvelity is already used for major depressive disorder (MDD), this new approval targets a condition with very few effective treatments. With a commercial launch set for June, the company is pivoting from a research-and-development-heavy biotech to a multi-product commercial powerhouse.

Today's Change

(

1.24

%) $

3.14

Current Price

$

256.91

Much of the Alzheimer's hype focuses on plaque-clearing drugs such as Leqembi. Axsome is tackling the behavioral side of the disease, which is often the primary reason patients are moved into long-term care facilities. This represents a massive, underserved market.

Auvelity was already seeing strong sales growth before the FDA's most recent decision. In 2025, Axsome reported full-year sales of $507.1 million for the drug, up 74%. The company's total revenue was $638.5 million, up 66%. It had an earnings per share (EPS) loss of $3.68, compared to an EPS loss of $5.69 in 2024.

The company's other products also saw double-digit growth. Sunosi, used to treat excessive daytime sleepiness, generated $124.8 million in revenue, up 32%, and migraine therapy Symbravo generated $6.6 million in its first year of sales.

NovoCure has a unique therapy NovoCure uses a proprietary technology called Tumor Treating Fields (TTFs) -- basically, electric fields that disrupt cancer cell division. In February, the FDA approved one of its TTFs, Optune Pax, for the treatment of advanced pancreatic cancer. The therapy provides a non-invasive option alongside chemotherapy. More than 52,000 people will die from pancreatic cancer in 2026, a disease that accounts for 8% of all cancer deaths, according to the National Cancer Institute.

Today's Change

(

0.45

%) $

0.08

Current Price

$

17.79

The stock has been volatile due to mixed results in other trials (such as lung cancer), leading some investors to write off the stock. However, the rapid certification of more than 800 healthcare providers immediately following this approval suggests that the clinical demand is far higher than the current market cap reflects.

The company reported that first-quarter revenue climbed 12% year over year to $174 million. This was mainly due to increased sales of Optune Gio, approved as monotherapy for brain metastasis and as combination therapy for glioblastoma, the most common malignant primary brain tumor. It was expected to affect nearly 14,000 people in the U.S. in 2025.

It is important to note that it will be a while before the company is profitable, as it is spending heavily on clinical trials and other R&D. It had a quarterly net loss of $71.1 million with an EPS loss of $0.62, compared to a loss of $34.3 million and an EPS loss of $0.31 in the same period a year ago.

MBX Biosciences is squeezing its way into the weight-loss sector For those looking at the next generation of the obesity and endocrine market, MBX is a quiet contender. The clinical-stage biotech focuses on protein endocrine pipeline (PEP) candidates designed to last longer and work better than current peptide drugs.

Today's Change

(

-5.97

%) $

-2.23

Current Price

$

35.02

Analysts are closely watching for a fourth-quarter readout of MBX's monthly GLP/GIP obesity candidate, MBX 4291. While Eli Lilly and Novo Nordisk dominate the weekly injection market, MBX aims for a once-a-month dosing schedule.

As a more recent entrant to the public markets, it hasn't enjoyed the same meme-stock status as other weight-loss names. However, its de-risked programs in rare endocrine diseases provide a valuation floor, while its obesity trials offer the high-upside moonshot potential.

MBX's pipeline also includes MBX 1416 (Phase 2 for post-bariatric hypoglycemia) and two preclinical obesity therapies.

The company doesn't have any product revenue, but it does have $459.1 million in cash. MBX said that that's enough to fund its operations into 2029.

This could be a breakthrough year for all three Small biotech stocks offer high rewards alongside a healthy dose of risk. Ultimately, 2026 is shaping up to be a year of validation for these diverse therapeutic approaches. Between Axsome's pivot toward behavioral neurology, NovoCure's unique electrical disruption of cancer cells, and MBX's pursuit of monthly dosing for metabolic health, the trio represents a high-upside cross-section of modern biotechnology.

As these companies continue to reach clinical readouts and commercial launch dates, the disparity between their current valuations and their market potential offers a compelling window for growth-oriented investors to capitalize on breakthroughs that are just beginning to reach the patients who need them most.

May 07, 2026 07:00 ET  | Source: Axsome Therapeutics, Inc.

NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced its support for Mental Health Month alongside the broader mental health advocacy community. In recognition of this year’s More Good Days Together theme, Axsome is sharing resources to support individuals affected by mental health conditions, their families, and the communities around them.

“At Mental Health America, we are proud to have established Mental Health Month in 1949, with the goal of educating the public about mental illness, mental health, and recovery,” said Pierluigi Mancini, PhD, interim president and CEO of Mental Health America (MHA). “Our 2026 campaign, More Good Days, Together, provides tools and resources that meet people where they are, support them as whole people, and acknowledge that 'good' is defined by their unique experience and goals. The path may look different for everyone, but we all deserve more good days, together."

Mental health conditions are highly prevalent in the U.S., with nearly 1 in 4 adults living with a mental illness.1 Major depressive disorder (MDD), one of the most common mental health conditions, is a leading cause of disability worldwide and impacts over 21 million adults in the U.S. alone.1-3 Nearly 90% of people living with depression report difficulty with work, home, or social activities due to their symptoms, underscoring the impact depression can have on day-to-day life.4

Axsome’s mission is to develop and deliver transformative medicines to improve the brain health of millions of individuals affected by central nervous system conditions, including those living with difficult-to-treat mental illness. To help raise awareness and promote action during Mental Health Month, Axsome is highlighting non-profit organizations and resources that provide education, tools, and community support for individuals and families affected by mental health conditions, including:

2026 Mental Health Month Action Guide (https://mhanational.org/2026-mental-health-month-action-guide/) MHA’s work is driven by its commitment to promote mental health as a critical part of overall wellness, including prevention services for all; early identification and intervention for those at risk; and integrated care, services, and support for those who need them, with recovery as the goal. Its 2026 Mental Health Month Action Guide provides access to online activities, articles, printable tools, and practical resourcesAnxiety and Depression Association of America (ADAA)’s “Find Your Therapist” platform (https://findyourtherapist.adaa.org/) helps connect people with licensed mental health professionals who specialize in treating anxiety, depression, OCD, PTSD, and other related disorders. This aligns with ADAA’s 2026 annual conference theme around “Innovations in Technology Driving Clinical Care and Research in Mood and Anxiety Disorders,” and the organizations commitment to improving live through collaboration, research, education, and innovation.   The National Alliance on Mental Illness (NAMI) New York Chapter (https://naminycmetro.org/), guided by lived experience and evidence-based practices, helps families and individuals affected by mental illness build better lives through education, support, and advocacy. Later this month NAMI-NYC is hosting its annual Mental Health Street Fest, which is the nation’s largest mental health event, being held since 2007: https://www.namiwalks.org/nyc.
If you or someone you know is in crisis, the 988 Suicide & Crisis Lifeline (https://988lifeline.org/) is a free confidential support service available 24 hours a day, 7 days a week across the United States. When people call, text, or chat 988, they will be connected to trained counselors that are part of the existing Lifeline network. These trained counselors will listen, understand how their problems are affecting them, provide support, and connect them to resources if necessary.

About Axsome Therapeutics

Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, agitation associated with dementia due to Alzheimer’s disease, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, as well as multiple novel product candidates addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at www.axsome.com and follow us on LinkedIn and X.

Forward Looking Statements

Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s SUNOSI®, AUVELITY®, and SYMBRAVO® products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company’s ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Investors:
Ashley Dong
Senior Director, Investor Relations
(929) 687-1614
[email protected]

Media:
Darren Opland
Senior Director, Corporate Communications
(929) 837-1065
[email protected]

References:

Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2023 National Survey on Drug Use and Health. July 2024. https://www.samhsa.gov/data/report/2023-nsduh-annual-national-reportWorld Health Organization. Depression and Other Common Mental Disorders: Global Health Estimates. 2017.https://www.who.int/publications/i/item/depression-global-health-estimatesNational Institute of Mental Health. Major Depression. Accessed February 2026. https://www.nimh.nih.gov/health/statistics/major-depressionBrody DJ, Hughes JP. Depression prevalence in adolescents and adults: United States, August 2021–August 2023. 2025 Apr; (527)1–11. DOI: https://dx.doi.org/10.15620/cdc/174579.

Axsome Therapeutics, Inc. (AXSM) Presents at Bank of America Global Healthcare Conference 2026 Transcript

May 26, 2026 07:00 ET  | Source: Axsome Therapeutics, Inc.

NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations of new AUVELITY® data in major depressive disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting being held from May 26-29 in Miami, FL.

Details of the presentations are as follows:

Title: Effects of Dextromethorphan-Bupropion (45 mg/105 mg) in Participants with Major Depressive Disorder and Anxious Distress
Presentation Date and Time: Wednesday, May 27, 11:45 a.m. - 1:30 p.m. ET
Lead Author: Jeffrey R. Strawn, MD, Professor of Psychiatry and Behavioral Neuroscience, University of Cincinnati, OH
Poster Number: W42 Title: Anxiolytic Effects of Dextromethorphan-Bupropion (45 mg/105 mg): Post Hoc Analyses Across Trials in Major Depressive Disorder
Presentation Date and Time: Wednesday, May 27, 11:45 a.m. - 1:30 p.m. ET
Lead Author: Jeffrey R. Strawn, MD, Professor of Psychiatry and Behavioral Neuroscience, University of Cincinnati, OH
Poster Number: W50 Title: Real-World Clinical Outcomes of Patients Switching to Treatment with Dextromethorphan-Bupropion (45 mg/105 mg) 
Presentation Date and Time: Thursday, May 28, 11:45 a.m. - 1:15 p.m. ET
Lead Author: Joel L. Young, MD, Medical Director of the Rochester Center for Behavioral Medicine, NY
Poster Number: T34 Title: Effects of Solriamfetol on Neuropsychological Outcomes in Patients with Obstructive Sleep Apnea in the Real-World SURWEY Study 
Presentation Date and Time: Thursday, May 28, 11:30 a.m. - 1:15 p.m. ET
Lead Author: Yaroslav Winter, MD, Mainz Comprehensive Epilepsy and Sleep Medicine Center, Department of Neurology, Johannes Gutenberg-University, Mainz, Germany
Poster Number: T29 About Axsome Therapeutics

Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, agitation associated with dementia due to Alzheimer’s disease, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, as well as multiple novel product candidates addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at www.axsome.com and follow us on LinkedIn and X.

Forward-Looking Statements

Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s SUNOSI®, AUVELITY®, and SYMBRAVO® products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company’s ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Investors:
Ashley Dong
Senior Director, Investor Relations
(929) 687-1614
[email protected]

Media:
Darren Opland
Senior Director, Corporate Communications
(929) 837-1065
[email protected]

June 01, 2026 07:00 ET  | Source: Axsome Therapeutics, Inc.

NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today highlighted its commitment to the migraine community by supporting educational initiatives during Migraine and Headache Awareness Month this June.

“People living with migraine and headache disorders deserve to be seen, believed, and supported with information and care that reflect the seriousness of these diseases,” said Julienne Verdi, Executive Director of The Headache Alliance and the Alliance for Headache Disorders Advocacy. “Awareness campaigns like Headache in the City help the public better understand the real impact of headache disease and why early diagnosis, treatment, and connection to care matter. The Headache Alliance is proud to lead educational and awareness efforts that reduce stigma, connect people with trusted resources, and help more people understand that better days are possible with the right care.”

Migraine is a debilitating condition characterized by recurrent attacks of pulsating, often severe and disabling head pain, accompanied by nausea, sensitivity to light, and/or sensitivity to sound.1 Migraine affects approximately 40 million people in the U.S. and is the second leading cause of disability worldwide.2,3

To help raise awareness for the impact that migraine has on millions of Americans that live in major cities, Axsome is supporting the first annual Headache in the City educational campaign from the Headache Alliance on June 15 in New York City. Additionally, on June 4, Axsome’s New York City headquarters, One World Trade Center, will be lit in purple, the color for migraine awareness, through the building’s Spireworks program, to help promote awareness efforts.

Axsome is also sharing the following resources from some of the leading migraine advocacy organizations:

American Migraine Foundation Find a Doctor (https://americanmigrainefoundation.org/find-a-doctor/) is a resource to help patients find medical professionals experienced in migraine and headache care.Association of Migraine Disorders Migraine Explainer Videos (https://www.migrainedisorders.org/education/patient-resources/videos/) are educational videos that describe different types of migraines, symptoms, treatments, and pathophysiology.CHAMP Financial Assistance Guides (https://headachemigraine.org/migraine-financial-assistance-guides/) outline financial assistance programs operated by pharmaceutical companies and device manufacturers to help patients cover the cost of accessing treatment.National Headache Foundation podcast (https://headaches.org/category/podcast/head-wise/) features informative discussions with headache experts on the latest treatment, research, lifestyle recommendations, and personal stories about living with migraine disease and headache disorders. About Axsome Therapeutics

Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, agitation associated with dementia due to Alzheimer’s disease, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, as well as multiple novel product candidates addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at www.axsome.com and follow us on LinkedIn and X.

Forward Looking Statements

Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s SUNOSI®, AUVELITY®, and SYMBRAVO® products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company’s ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Investors:
Ashley Dong
Senior Director, Investor Relations
(929) 687-1614
[email protected]

Media:
Darren Opland
Senior Director, Corporate Communications
(929) 837-1065
[email protected]

References:

Headache Classification Committee of the International Headache Society (IHS) Cephalalgia (2018)American Migraine Foundation (2023), https://americanmigrainefoundation.org/, accessed May 2, 2025.Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z. Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020 Dec 2;21(1):137.

It has been about a month since the last earnings report for Axsome Therapeutics (AXSM - Free Report) . Shares have lost about 0.4% in that time frame, underperforming the S&P 500.

But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Axsome due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.

Axsome Q1 Loss Widens, Revenues Rise on Higher Auvelity SalesAxsome incurred a loss of $1.26 per share in the first quarter of 2026, wider than the Zacks Consensus Estimate of a loss of 85 cents. The company had reported a loss of $1.22 per share in the year-ago quarter.

Axsome’s total revenues surged 57.4% year over year to $191.2 million in the first quarter, beating the Zacks Consensus Estimate of $189 million. The year-over-year increase in revenues was primarily driven by strong sales of Auvelity as well as other marketed drugs.

Quarter in DetailTotal revenues in the first quarter consisted of product revenues from Auvelity, Sunosi, and the newest drug, Symbravo, as well as royalty and milestone revenues.

Net product revenues were $189.4 million in the quarter, reflecting an increase of 57.4% year over year. Royalty and milestone revenues totaled $1.8 million in the quarter, reflecting royalties on Sunosi’s sales in out-licensed territories.

Auvelity recorded sales of $153.2 million, up 59% from the year-ago quarter’s level. Sales of the drug beat the Zacks Consensus Estimate of $144 million.

Per Axsome, around 223,000 prescriptions were recorded for Auvelity in the first quarter, reflecting a year-over-year increase of 35%.

Sunosi’s net product sales were $33.9 million in the quarter, up 34% from the year-ago quarter’s level. Total prescriptions for Sunosi in the United States grew 16% year over year to 54,000.

Axsome’s newest drug, Symbravo, was launched in June 2025 in the United States. Sales of the drug came in at $4.1 million in the first quarter and were flat sequentially. Symbravo’s sales missed the Zacks Consensus Estimate of $6.7 million.

Total prescriptions for Symbravo grew 36% sequentially to 17,000 in the first quarter of 2026.

Research and development expenses (including stock-based compensation) were $52.7 million, up 17.6% from the year-ago quarter’s level, due to a one-time acquisition-related expense.

Selling, general and administrative expenses (including stock-based compensation) totaled $185 million, up 53.1% year over year. The increase was due to higher commercial activities for Auvelity and Symbravo, and also the ongoing pre-launch activities for Auvelity for the Alzheimer’s disease agitation indication.

As of March 31, 2026, Axsome had cash and cash equivalents worth $305.1 million compared with $322.9 million as of Dec. 31, 2025.

How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a downward trend in estimates revision.

The consensus estimate has shifted -69.78% due to these changes.

VGM ScoresAt this time, Axsome has a great Growth Score of A, though it is lagging a lot on the Momentum Score front with an F. Charting a somewhat similar path, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for value investors.

Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, Axsome has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Axsome Therapeutics, Inc. (AXSM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced DAYBUE® STIX (trofinetide) for oral solution, a dye- and preservative-free powder formulation of trofinetide, is now broadly available in the United States for the treatment of Rett syndrome in adults and pediatric patients two years of age and older. The new formulation, approved by the U.S. Food and Drug Administration (FDA) in December 2025, is bioequivalent to the original DAYBUE® oral solution, delivering the same efficacy and safety profile, while offering children and adults living with Rett syndrome new flexibility and choice regarding the dose volume and taste of their DAYBUE treatment.1

"Initial feedback from a small group of caregivers following the limited launch revealed that more than 80% of early users reported satisfaction with DAYBUE STIX, highlighting the added flexibility and portability of this new formulation,"2 said Tom Garner, Acadia’s Chief Commercial Officer. “We are hearing that the new formulation may allow for more customized care in real-world settings. Ongoing evaluation from patients and caregivers remains a priority; their perspectives are essential as we identify ways to better assist families managing this complex condition.”

The importance of flexible, patient-centered approaches was reinforced in a recent publication of expert recommendations for real-world use of trofinetide in Rett syndrome. A steering group comprised of experts based at International Rett Syndrome Foundation (IRSF)-designated centers of excellence (COEs) reached consensus recognizing trofinetide oral solution as part of the standard of care for individuals with Rett syndrome. They also aligned on key real-world considerations such as early initiation and sustained use over time. The recommendations also reflect shared perspectives on the need for individualized decision making in clinical practice to help optimize outcomes for patients, families, and caregivers.3

“The availability of DAYBUE STIX gives us an additional, flexible way to administer trofinetide, which allows us more options to address unique patient and caregiver needs,” said Arthur Beisang, M.D., Department of Pediatrics, Gillette Children's Specialty Healthcare, Saint Paul, Minn. “This patient-centered approach aligns with recently published expert consensus recommendations, which advocate for the integration of trofinetide as part of the standard of care and comprehensive Rett syndrome management. This new option provides additional customization, supporting individualized care for people with Rett syndrome.”

DAYBUE STIX is a for oral solution powder that caregivers can mix with a variety of water-based liquids such as juice, tea, lemonade, limeade, or liquid hydration so that caregivers have the ability to customize to their loved ones' taste.4 The product comes in individual packets that are easily portable.

The efficacy and safety of DAYBUE STIX is based on the results of the pivotal Phase 3 LAVENDER™ study with DAYBUE oral solution in patients with Rett syndrome.4 The approval of this new formulation was informed by the results of a bioequivalence study, which demonstrated that both original DAYBUE oral solution and the new DAYBUE STIX for oral solution powder formulation provide comparable exposure.1

Families interested in exploring this new option should speak with their healthcare provider. Acadia also offers families access to Acadia Connect®, a multi-faceted support program that offers a dedicated, experienced support team assisting with financial resources and prescription support to patients and caregivers throughout the DAYBUE treatment journey. The original oral solution formulation approved by the U.S. Food and Drug Administration in 2023 will remain available.

About Rett Syndrome

Rett syndrome is a rare, complex, neurodevelopmental disorder that may occur over four stages and occurs in approximately one of every 10,000 to 15,000 female births worldwide.5-7 In the U.S., 6,000 to 9,000 patients are affected.8 A child with Rett syndrome exhibits an early period of apparently normal development until six to 18 months, when their skills seem to slow down or stagnate. This is typically followed by a duration of regression when the child loses acquired communication skills and purposeful hand use. The child may then experience a plateau period in which they show mild recovery in cognitive interests, but body movements remain severely diminished. As they age, those living with Rett may continue to experience a stage of motor deterioration, which can last the rest of the patient’s life.6 Rett syndrome is typically caused by a genetic mutation on the MECP2 gene.9 In preclinical studies, deficiency in MeCP2 function is thought to lead to impairment in synaptic communication, and the deficits in synaptic function may be associated with Rett manifestations.9-11

Symptoms of Rett syndrome may also include development of hand stereotypies, such as hand wringing and clapping, and gait abnormalities.12 Most Rett patients typically live into adulthood and require round-the-clock care.5,13

About DAYBUE® (trofinetide) and DAYBUE® STIX (trofinetide)

Trofinetide is a synthetic analog of the N-terminal tripeptide of insulin-like growth factor-1. The mechanism by which trofinetide exerts therapeutic effects in patients with Rett syndrome is unknown. In animal studies, trofinetide has been shown to increase branching of dendrites and synaptic plasticity signals.14

Indication and Important Safety Information for DAYBUE® (trofinetide) and DAYBUE® STIX (trofinetide)

Indication

DAYBUE and DAYBUE STIX are indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older.

Important Safety Information

Warnings and Precautions Diarrhea: In a 12-week study and in long-term studies, 85% of patients treated with DAYBUE experienced diarrhea. In those treated with DAYBUE, 49% either had persistent diarrhea or recurrence after resolution despite dose interruptions, reductions, or concomitant antidiarrheal therapy. Diarrhea severity was mild or moderate in 96% of cases. In the 12-week study, antidiarrheal medication was used in 51% of patients treated with DAYBUE.
Advise patients to stop laxatives before starting DAYBUE or DAYBUE STIX. If diarrhea occurs, patients should notify their healthcare provider, consider starting antidiarrheal treatment, and monitor hydration status and increase oral fluids, if needed. Interrupt, reduce dose, or discontinue DAYBUE or DAYBUE STIX if severe diarrhea occurs or if dehydration is suspected. Vomiting: In a 12-week study, vomiting occurred in 29% of patients treated with DAYBUE and in 12% of patients who received placebo.
Patients with Rett syndrome are at risk for aspiration and aspiration pneumonia. Aspiration and aspiration pneumonia have been reported following vomiting in patients being treated with DAYBUE. Interrupt, reduce dose, or discontinue DAYBUE or DAYBUE STIX if vomiting is severe or occurs despite medical management. Weight Loss: In the 12-week study, 12% of patients treated with DAYBUE experienced weight loss of greater than 7% from baseline, compared to 4% of patients who received placebo. In long-term studies, 2.2% of patients discontinued treatment with DAYBUE due to weight loss. Monitor weight and interrupt, reduce dose, or discontinue DAYBUE or DAYBUE STIX if significant weight loss occurs. Adverse Reactions: The common adverse reactions (≥5% for DAYBUE-treated patients and at least 2% greater than in placebo) reported in the 12-week study were diarrhea (82% vs 20%), vomiting (29% vs 12%), fever (9% vs 4%), seizure (9% vs 6%), anxiety (8% vs 1%), decreased appetite (8% vs 2%), fatigue (8% vs 2%), and nasopharyngitis (5% vs 1%). Drug Interactions: Effect of DAYBUE and DAYBUE STIX on other Drugs Trofinetide, a weak inhibitor of CYP3A and an inhibitor of P-gp, can increase the plasma concentrations of CYP3A and/or P-gp substrates (e.g., loperamide), which may increase the risk of adverse reactions associated with these substrates.
Closely monitor patients when DAYBUE or DAYBUE STIX is administered concomitantly with sensitive CYP3A and/or P-gp substrates for which a minimal increase in substrate plasma concentration (i.e., drugs with a narrow therapeutic index) may lead to serious adverse reactions. Use in Specific Population: Renal Impairment DAYBUE and DAYBUE STIX are not recommended for patients with severe renal impairment. DAYBUE is available as an oral solution (200 mg/mL).

DAYBUE STIX for oral solution powder is available in 5,000 mg, 6,000 mg, and 8,000 mg packets.

Please read the full Prescribing Information also available at DAYBUEhcp.com.

About Acadia Pharmaceuticals

Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we’re here to be their difference. For more information, visit us at acadia.com and follow us on LinkedIn and X.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact and can be identified by terms such as “may,” “will,” “should,” “expects,” “anticipates,” and similar expressions (including the negative thereof) intended to identify forward-looking statements. Forward-looking statements contained in this press release, include, but are not limited to, statements about: (i) the efficacy and safety profile of DAYBUE and DAYBUE STIX and anticipated Rett syndrome symptom improvements, (ii) the flexibility in administration and allowance for customized care provided by DAYBUE STIX, (iii) the use of DAYBUE and DAYBUE STIX as the standard of care for patients with Rett syndrome and (iv) potential future use of DAYBUE and DAYBUE STIX. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. Such risks, uncertainties, assumptions and other factors include, but are not limited to: our ability to continue to successfully commercialize DAYBUE and DAYBUE STIX and our ability to continue to stay in compliance with applicable laws and regulations. Given the risks and uncertainties, you should not place undue reliance on these forward-looking statements. For a discussion of these and other risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to differ, please refer to our annual report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission on February 26, 2026, as well as our subsequent filings with the Securities and Exchange Commission from time to time. The forward-looking statements contained herein are made as of the date hereof, and we undertake no obligation to update them after this date, except as required by law.

References

1

Mona D, Yamamoto A, Adegbenle Y, et al. A Phase 1, Randomized, Open-Label Study to Assess the Bioequivalence of Trofinetide as a Ready-to-Use Oral Solution and Constituted Powder for Oral Solution in Healthy Adults. Adv Ther. 2026.

2

Acadia Pharmaceuticals Inc., Data on file.

3

Prange EO, Beisang A, Pehlivan D, et al. Expert Consensus on Real-World Use of Trofinetide for Rett Syndrome Using a Modified Delphi Method. Ann Child Neurol. 2026; 4:38-51

4

Acadia Pharmaceuticals Inc. DAYBUE® [package insert]. San Diego, CA; 2025

5

Fu C, Armstrong D, Marsh E, et al. Consensus guidelines on managing Rett syndrome across the lifespan. BMJ Paediatrics Open. 2020; 4:1-14.

6

Kyle SM, Vashi N, Justice MJ. Rett syndrome: a neurological disorder with metabolic components. Open Biol. 2018; 8:170216.

7

May DM, Neul JL, Satija A, et al. Real-world clinical management of individuals with Rett syndrome: a physician survey. J of Med Econ. 26(1), 1570–1580.

8

Acadia Pharmaceuticals Inc., Data on file. RTT US Prevalence. March 2022.

9

Amir RE, Van den Veyver IB, Wan M, et al. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet. 1999; 23(2):185-188.

10

Fukuda T, Itoh M, Ichikawa T, et al. Delayed maturation of neuronal architecture and synaptogenesis in cerebral cortex of Mecp2-deficient mice. J Neuropathol Exp Neurol. 2005; 64(6):537-544.

11

Asaka Y, Jugloff DG, Zhang L, et al. Hippocampal synaptic plasticity is impaired in the Mecp2-null mouse model of Rett syndrome. Neurobiol Dis. 2006; 21(1):217-227.

12

Neul JL, Kaufmann WE, Glaze DG, et al. Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol. 2010; 68(6):944-950.

13

Tarquinio DO, Hou W, Neul JL, et al. The changing face of survival in Rett syndrome and MECP2-related disorders. Pediatr Neurol. 2015; 53(5):402-411.

14

Acadia Pharmaceuticals Inc., Data on file. Study Report 2566-026. 2010.

More News From Acadia Pharmaceuticals Inc.

Posted by Defense World Staff on Apr 9th, 2026

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) EVP Mark Schneyer sold 2,709 shares of the firm’s stock in a transaction on Tuesday, April 7th. The shares were sold at an average price of $22.20, for a total value of $60,139.80. Following the transaction, the executive vice president directly owned 62,836 shares in the company, valued at $1,394,959.20. This trade represents a 4.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

ACADIA Pharmaceuticals Stock Performance Shares of ACAD opened at $22.56 on Thursday. The firm has a market capitalization of $3.85 billion, a price-to-earnings ratio of 9.85, a price-to-earnings-growth ratio of 22.07 and a beta of 0.83. ACADIA Pharmaceuticals Inc. has a one year low of $13.40 and a one year high of $28.35. The stock’s fifty day moving average is $22.69 and its 200-day moving average is $23.79.

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) last released its earnings results on Thursday, February 26th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.12 by $1.48. The firm had revenue of $298.00 million for the quarter, compared to analyst estimates of $292.54 million. ACADIA Pharmaceuticals had a return on equity of 12.49% and a net margin of 36.49%.ACADIA Pharmaceuticals’s revenue was up 9.4% compared to the same quarter last year. During the same period in the previous year, the company earned $0.86 earnings per share. Analysts forecast that ACADIA Pharmaceuticals Inc. will post 0.7 EPS for the current fiscal year.

More ACADIA Pharmaceuticals News Here are the key news stories impacting ACADIA Pharmaceuticals this week:

Positive Sentiment: Analysts/Zacks note ACAD’s history of quarterly earnings surprises and say the company currently has the key attributes that make another beat likely — supporting upside into the next report. Will Acadia (ACAD) Beat Estimates Again in Its Next Earnings Report? (Yahoo) Will Acadia (ACAD) Beat Estimates Again in Its Next Earnings Report? (Zacks) Positive Sentiment: Acadia launched DAYBUE® STIX (trofinetide) — a dye- and preservative-free powder formulation of its Rett syndrome medicine — and said it is now broadly available in the U.S.; FDA-approved bioequivalence and easier dosing could boost uptake and sales. Acadia Announces DAYBUE STIX Now Broadly Available (BusinessWire) Positive Sentiment: Analyst coverage and institutional activity are constructive: several firms raised price targets or hold “outperform/overweight” views, and reports show large institutional stakes increasing — a supportive backdrop for the shares. Acadia Pharmaceuticals: A Mid-Cap Biotech Making Large Moves (MarketBeat) Neutral Sentiment: Recent fundamentals: ACAD posted a sizable EPS beat in its last quarter (reported $1.60 vs. $0.12 est.) and revenue growth (~9% y/y); valuation metrics (low-teens P/E) and its 50/200-day moving averages are mixed signals for different investor horizons. ACAD Price & Profile (MarketBeat) Negative Sentiment: Insider selling: EVP Mark C. Schneyer sold 2,709 shares and director/executive James Kihara sold 1,030 shares at about $22.20 on April 7; while dollar amounts are modest relative to institutional holdings, insider sales can raise short-term caution for some investors. James Kihara Sells 1,030 Shares of ACADIA Pharmaceuticals (InsiderTrades) SEC Form 4 (Kihara) SEC Form 4 (Schneyer) Hedge Funds Weigh In On ACADIA Pharmaceuticals Hedge funds and other institutional investors have recently modified their holdings of the stock. Farther Finance Advisors LLC boosted its position in shares of ACADIA Pharmaceuticals by 67.5% in the 4th quarter. Farther Finance Advisors LLC now owns 958 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 386 shares during the period. Meeder Asset Management Inc. acquired a new position in shares of ACADIA Pharmaceuticals in the 4th quarter valued at $26,000. Geneos Wealth Management Inc. boosted its position in shares of ACADIA Pharmaceuticals by 113.0% in the 3rd quarter. Geneos Wealth Management Inc. now owns 1,425 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 756 shares during the period. Smartleaf Asset Management LLC boosted its position in shares of ACADIA Pharmaceuticals by 107.0% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,712 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 885 shares during the period. Finally, Transamerica Financial Advisors LLC boosted its position in shares of ACADIA Pharmaceuticals by 304.5% in the 4th quarter. Transamerica Financial Advisors LLC now owns 1,335 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 1,005 shares during the period. Institutional investors and hedge funds own 96.71% of the company’s stock.

Analyst Ratings Changes A number of research firms recently issued reports on ACAD. JPMorgan Chase & Co. lifted their target price on ACADIA Pharmaceuticals from $31.00 to $34.00 and gave the stock an “overweight” rating in a report on Wednesday, March 4th. Citizens Jmp lifted their target price on ACADIA Pharmaceuticals from $34.00 to $35.00 and gave the stock a “market outperform” rating in a report on Thursday, February 26th. Piper Sandler set a $37.00 target price on ACADIA Pharmaceuticals in a report on Tuesday, December 16th. Oppenheimer reaffirmed a “market perform” rating on shares of ACADIA Pharmaceuticals in a report on Friday, February 6th. Finally, Wolfe Research began coverage on ACADIA Pharmaceuticals in a report on Monday, February 23rd. They set an “outperform” rating and a $33.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, ACADIA Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $31.21.

Check Out Our Latest Research Report on ACAD

About ACADIA Pharmaceuticals (Get Free Report)

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.

Featured Stories Five stocks we like better than ACADIA Pharmaceuticals

Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINELarry Madden Sells 7,297 Shares of Viant Technology (NASDAQ:DSP) Stock

NEXT HEADLINE »Gershon Distenfeld Sells 5,462 Shares of AllianceBernstein Global High Income Fund (NYSE:AWF) Stock

-

Company to host conference call and webcast on Wednesday, May 6, 2026, at 4:30 p.m. Eastern Time

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter 2026 financial results on Wednesday, May 6, 2026, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on May 6, 2026, at 4:30 p.m. Eastern Time.

The conference call will be available on Acadia’s website, acadia.com under the investors section and will be archived there until August 15, 2026. The conference call may also be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in number and unique PIN number to use for accessing the call.

About Acadia Pharmaceuticals

Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we’re here to be their difference. For more information, visit us at acadia.com and follow us on LinkedIn and X.

More News From Acadia Pharmaceuticals Inc.

Back to Newsroom